This deal could have huge effect to $jnj Daratumumab because $SNY is doing comination trial NK + CD38 SARCLISA. $ATNM is doing similar trial Ac225 +CD38 Daratumumab. @JNJInnovation needs to step up sign licensing  deal with @ActiniumPharma before @SanofiUS buyout @ActiniumPharma https://t.co/Yhe7mIJc30